Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA

Methods for stabilizing one or more peroxide compounds in solution comprising adding to the solution an effective amount of at least one compound selected from the group comprising (i) cyclic carbonates; (ii) poly-phosphonic acid chelating agents and salts thereof, and alkaline pH adjusting agents with a pKb value of up to 3.0, wherein the w/w ratio of the poly-phosphonic acid chelating agent or salt thereof to alkali or alkaline earth metal hydroxide is from about 1:1 to about 50:1; and (iii) mixtures thereof. Also disclosed are solutions comprising the above compounds, uses of the above compounds to stabilize peroxide compounds in solutions, and compounds recited above for use as novel stabilizers.

Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-2-cyano-1-(2,6-dichloropyridin-4-yl)-3-((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)guanidine and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

An infrared-absorbing composition according to the present invention includes: an infrared absorber formed by a phosphonic acid represented by the following formula (a) and copper ion; and a phosphoric acid ester allowing the infrared absorber to be dispersed. The phosphoric acid ester includes at least one of a phosphoric acid diester and a phosphoric acid monoester. R.sub.1 is a phenyl group or a phenyl group in which at least one hydrogen atom is substituted by a halogen atom. When molar contents of the phosphonic acid, the copper ion, and the phosphoric acid ester are respectively defined as C.sub.A mol, C.sub.C mol, and C.sub.E mol and a total molar content of reactive hydroxy groups is defined as C.sub.H mol, the relations C.sub.A/C.sub.E<1 and C.sub.H/C.sub.C>1.95 are satisfied. ##STR00001##

The present disclosure provides a pressure-reducing and injection-enhancing anti-scaling agent for low-permeability water-injection wells and a preparation method thereof. The anti-scaling agent is prepared from starting materials comprising: 10 to 12 parts of non-ionic surfactant(s), 18 to 20 parts of hexasodium triethylenetetramine-N,N,N,N,N,N-hexaacetate, 5 to 8 parts of anionic surfactant(s), 6 to 8 parts of an organic phosphonic acid-carboxylic acid scale inhibitor, 2 to 5 parts of a dispersant, 15 to 18 parts of a diluent, 8 to 10 parts of an organic amine salt, and 30 to 36 parts of water. The pressure-reducing and injection-enhancing agent according to the present disclosure is characterized by having multiple functions in one agent. When used in an amount being 0.5% of the water injected to a water injection well, it shows excellent anti-swelling property, shrinking property, anti-corrosive property, and calcium sulfate and barium (strontium) sulfate scale resistance.

Niclosamide is an effective therapeutic medicament for the treatment of endometriosis. Niclosamide treatment can reduce the size of endometriotic lesions and reduce cell proliferation in the lesions. Niclosamide treatment can result in the inhibition of proteins and genes associated with inflammatory signaling, including those associated with NFB and STAT3 activation, but without altering the expression of steroid hormone receptors. Niclosamide can be effective in reducing the growth of endometriotic lesions in female mice without impairing their ability to become pregnant and without negative effect on gestation and offspring. The invention herein is useful in treating symptoms associated with endometriosis, such as reducing the growth of lesions of the endometrium, without disrupting normal reproductive function in females. The invention also relates to derivatives of niclosamide having improved solubility and enhanced efficacy.

The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.

A method of making a phosphono-phosphate compound is disclosed. The method involves a first step of mixing a first component comprising a phosphonic acid, a phosphonate or mixtures thereof, with a second component comprising a source of phosphoric acid or phosphate. The mixture has a molar phosphorous ratio of the first component to the second component of from 1:1 to 1:10. The second step involves either physically or chemically dehydrating the mixture to produce a phosphono-phosphate compound.

Downhole tools, methods, and systems related thereto. An example downhole tool includes a body comprising a degradable core and a chelating agent or a chelating agent/scale inhibitor mixture integrated therein. The chelating agent and scale inhibitors help to direct and control the degradation of the degradable core.